SCHEMBL3639698

SCHEMBL3639698

COc1ccc(-c2cccc(C(=O)O)c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.74
RAB9A P51151 3/20 0.74
MEN1 O00255 3/20 0.74
KMT2A Q03164 3/20 0.74
NPC1 O15118 1/20 0.74
LMNA P02545 2/20 0.71
GAA P10253 1/20 0.71
ERCC5 P28715 1/20 0.67
FEN1 P39748 1/20 0.67
HPGD P15428 2/20 0.65
ALDH1A1 P00352 2/20 0.65
KDM4E B2RXH2 1/20 0.65
KMO O15229 1/20 0.65
TSHR P16473 1/20 0.64
MAPK1 P28482 1/20 0.61
TP53 P04637 1/20 0.59
PKM P14618 1/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254012 0.88 STIM1 (0.62) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL27616105 0.88 HPGD (0.66) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL8479394 0.86 HPGD (0.64) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL4179829 0.86 RXRA (0.67) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL14683877 0.85 KMO (0.87) LMNAGAAKMOCA1CA2
SCHEMBL29577419 0.85 KMO (0.87) LMNAGAAKMOCA1CA2
SCHEMBL23289051 0.85 HPGD (0.62) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL30913837 0.85 HPGD (0.62) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL7825137 0.85 PLAU (0.66) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3720494 0.85 PARP1 (0.67) SMN1; SMN2RAB9AMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117623975-A Allyl-containing alpha-quaternary carbon secondary amine compound and oxazine compound synthesized by same and containing quaternary carbon center 扬州大学 2024-03-01 CN claimed
EP-2167077-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-31 EP claimed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 US claimed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 WO claimed
US-20250221966-A1 RXFP1 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2025-07-10 US disclosed
WO-2025049326-A1 TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 BIOCRYST PHARMACEUTICALS, INC. (US) 2025-03-06 WO disclosed
US-20250049765-A1 BICYCLO [3.2.0] HEPTANE BIS(AMIDE) RXFP1 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2025-02-13 US disclosed
US-20240389450-A1 LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE Sharp Display Technology Corporation (JP) 2024-11-21 US disclosed
CN-118843613-A RXFP1 agonists 百时美施贵宝公司 2024-10-25 CN disclosed
EP-4448508-A1 BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS Bristol-Myers Squibb Company (US) 2024-10-23 EP disclosed
CN-118647606-A Benzothiophene derivatives as RXFP1 agonists 百时美施贵宝公司 2024-09-13 CN disclosed
EP-4422746-A1 RXFP1 AGONISTS Bristol-Myers Squibb Company (US) 2024-09-04 EP disclosed
US-6090817-A Phenylpyridine derivatives useful as phosphodiesterase inhibitors NOVARTIS AG (CH) 2000-07-18 US disclosed
US-5824691-A CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-10-20 US disclosed
US-5545645-A Heterocyclic derivatives in the treatment of ischaemia and related diseases SYNTEX PHARMACEUTICALS, LIMITED (GB) 1996-08-13 US disclosed
EP-0699185-A1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-03-06 EP disclosed
EP-0693062-A1 HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES SYNTEX PHARMACEUTICALS LTD. (GB) 1996-01-24 EP disclosed
US-5428037-A Piperazine derivatives; calcium and sodium channel antagonists SYNTEX PHARMACEUTICALS, LTD. (GB) 1995-06-27 US disclosed
WO-1994026709-A1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-24 WO disclosed
WO-1994024116-A1 HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES SYNTEX PHARMACEUTICALS LIMITED (GB) 1994-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221966-A1 RXFP1 AGONISTS RXFP1, RXFP2, RXFP3 SMN1; SMN2 4221/4885RAB9A 1052/4885MEN1 2822/4885
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 SMN1; SMN2 4144/4885RAB9A 3569/4885MEN1 4355/4885
US-20250049765-A1 BICYCLO [3.2.0] HEPTANE BIS(AMIDE) RXFP1 AGONISTS RXFP1, RXFP2, RXFP3 SMN1; SMN2 4469/4885RAB9A 1358/4885MEN1 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.